Cytokinetics Inc vs Amplify Cybersecurity ETF — how do they compare? Cytokinetics Inc trades at $77.54 (market cap $10.78B), while Amplify Cybersecurity ETF trades at $118.43. The key difference: Amplify Cybersecurity ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | HACK | |
|---|---|---|
Market Cap | $10.78B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $87.26 | $119.19 |
52-Week Low | $33.23 | $70.69 |
Enterprise Value | $10.88B | — |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
HACK is trading at $115.42, up 1.97% with strong bullish momentum from moving averages. The ETF recently hit a 52-week high and is positioned to benefit from escalating cybersecurity spending, which is forecast to exceed $300 billion in 2026. Technical indicators show the stock is near resistance at $116 with RSI suggesting mild overbought conditions. Institutional interest is growing, with D.A. Davidson increasing its position by 44.8% in Q1 2026.
The outlook remains positive as AI-driven cyber threats fuel demand for cybersecurity solutions. Key risks include market volatility and competitive pressures from other cybersecurity ETFs. Analyst sentiment is bullish with the ETF capturing the full cybersecurity stack as enterprises increase digital defense budgets amid rising AI-powered threats.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →